Added to YB: 2025-02-04
Pitch date: 2025-02-02
ACOG [bullish]
Alpha Cognition Inc.
+2.63%
current return
Author Info
Adventures in Stocks is a credit investor for 15+ years on both sell and buy side. Increasingly focussed on the PA and public equities. Sign up for the newsletter.
Company Info
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.
Market Cap
$106.1M
Pitch Price
$5.70
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.09
P/E
-3.67
EV/Sales
9.52
Sector
Biotechnology
Category
growth
Alpha Cognition $ACOG: too good to be true?
ACOG: FDA-approved ZUNVEYL for Alzheimer's, better tolerated than Benzgalantamine. 1Q25 launch, targeting $2bn LTC market. 20% share = $600M revenue, $445M EBITDA. $54.5M raised, no near-term dilution risk. Upside potential: $1.4B EV vs $120M cap. Risks: low insider ownership, execution, competition.
Read full article (3 min)